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Aims: This study tested inhibitory effects of in vitro Montelukast treatment on nasal airway
epithelial cells (AEC) cultured from asthmatic patients treated with Montelukast with and
without concomitant allergic rhinitis. We further examined the effect of Montelukast with-
drawal in these patients on cytokine release from cultured nasal AEC.
Methods: Nasal AEC were collected by brushings from subjects with a history of stable (no ex-
acerbations or change in medication for 1 month) physician confirmed mild/moderate
asthma whose asthma symptoms were documented to benefit from Montelukast treatment
(NCT01230437). Release of the following mediators by nasal AEC were measured: IL-8, IL-6,
IL-10, GM-CSF, RANTES, eotaxin and IFN-g. Nasal AEC were cultured before and one week after
withdrawal of their Montelukast treatment.
Results: Forty two asthmatics were recruited. Nasal AEC were successfully cultured in 17 at
the first assessment, 14 at the second assessment and in 10 individuals at both assessments.
Nasal AEC release was no different between asthmatics with or without allergic rhinitis. Mon-
telukast significantly suppressed the release of IL-8 (p Z 0.016), IL-6 (p Z 0.006), RANTES
(p Z 0.002) and IFN-g (p Z 0.046), in a dose dependent manner in unstimulated cultures
but not in those stimulated with IL-1/TNF. Withdrawal of Montelukast treatment, was associ-
ated with increased IL-8 and RANTES secretion in unstimulated nasal AEC cultured from sub-
jects with asthma and allergic rhinitis but not with asthma alone.pplied Medicine, School of Medicine & Dentistry, Institute of Medical Sciences, Aberdeen AB25 2ZG,
1224 438469.
c.uk (G.M. Walsh).
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1860 A. Scaife et al.Conclusions: Montelukast treatment for asthma symptoms reversibly suppresses nasal AEC
release of pro-inflammatory mediators (i.e. IL-8 and RANTES) but only in those cells cultured
from subjects with concomitant allergic rhinitis.
ª 2013 Elsevier Ltd. All rights reserved.Introduction
Asthma is a chronic inflammatory condition of the airways
characterised by histopathological changes in the epithe-
lium and submucosa. Histological alterations in the asth-
matic airway include goblet cell metaplasia, squamous
metaplasia, thickening of the lamina reticularis and an
accumulation of both subepithelial and intraepithelial in-
flammatory cells [1]. Increasingly strong evidence indicates
that the airway epithelium serves as a key orchestrator of
the events leading to asthma [2]. Production of cytokines
by the epithelium has been of particular interest with re-
gard to allergic and asthmatic inflammation as these factors
can influence infiltrating pro-inflammatory cells such as
eosinophils, T-lymphocytes and mast cells [3] and also
contribute to airway remodelling [4,5]. Increased suscep-
tibility of airway epithelial cells (AEC) to injury and
impaired epithelial proliferation lead to persistent mucosal
injury and cause AEC to spend longer in a repair phenotype,
resulting in increased production of pro-inflammatory me-
diators and increased secretion of pro-fibrogenic growth
factors which are capable of inducing proliferation of sub-
epithelial fibroblasts and their differentiation into acti-
vated myofibroblasts [1]. Furthermore, genetic studies
have identified several asthma susceptibility genes sug-
gesting a role for communication of epithelial damage to
the adaptive immune system and activation of airway
inflammation [6].
The cysteinyl leukotrienes (CysLTs) are potent lipid
mediators implicated in the pathophysiology of asthma and
allergic rhinitis (AR) whose effects include increased airway
smooth muscle activity, microvascular permeability and
airway mucus secretion [7]. CysLT(1) receptor antagonists
such as Montelukast can be given orally as monotherapy in
patients with mild persistent asthma [8], however for the
most part these drugs are less effective than inhaled cor-
ticosteroids and are often used in an adjunct fashion [9].
Antagonism of the cysLT1R with Montelukast has a number
of anti-inflammatory effects some of which appear inde-
pendent of cysLT1R antagonism [10]. These include inhibi-
tion of plasma protein extravasation and eosinophil
accumulation in small intra-parenchymal bronchi induced
by ovalbumin challenge of sensitised guinea pigs [11] and
inhibition of unstimulated and GM-CSF-stimulated eosino-
phil adhesion to VCAM-1 under shear stress conditions [12].
Montelukast also inhibited activation of NF-kB in a human
monocyte/macrophage cell line [13] and suppressed IL-8
gene transcription and protein synthesis in a monocyte/
macrophage cell line pre-treated with TNF [14].
We have developed a straightforward method for
establishing primary cultures of nasal AEC from nasal
brushings taken from adults [15] or children [16]. Our
findings demonstrate that paired cultures of nasal andbronchial epithelial cells from these subjects are similar in
size, shape and growth characteristics with a number of
similarities in cytokine/chemokine secretion. We have not
explored whether allergic rhinitis affects nasal AEC func-
tion and this is important in determining whether nasal AEC
are a valid surrogate for bronchial AEC. The aim of the
present study was to compare inflammatory cytokine pro-
duction by nasal AEC cultured from asthmatic patients with
and without concomitant AR and to examine whether
in vitro treatment with Montelukast has any suppressive
effects on mediator release from cultured nasal AEC.
Montelukast is known to be effective in reducing symptoms
of AR in asthmatic patients [17] and there is considerable
interest in the hypothesis of the link between asthma and
AR in the context of united airways disease [18,19]. The
secondary outcome of the study therefore, was to examine
pro-inflammatory cytokine and chemokine secretion by
nasal AEC in a sub-group of Montelukast-responsive patients
with asthma or asthma/AR after withdrawal of their Mon-
telukast for one week.Methods
Study design
Subjects with a history of stable (no exacerbations or
change in medication for 1 month) physician confirmed
mild/moderate asthma (Steps 1e4 of BTS/SIGN guidelines
[20]) with <10 pack-year smoking histories were recruited
from eight general practices in Grampian and the chest
clinic at Aberdeen Royal Infirmary. To be included in the
study participants had to be regularly prescribed Mon-
telukast and to have had a documented beneficial response
(symptoms, lung function, exacerbations) to the first pre-
scription of Montelukast recorded in the medical notes. The
presence or absence of AR was ascertained using the
symptoms recommended by the ARIA 2008 Guidelines [21].
Of 47 asthmatic individuals who consented to take part in
the study, 2 (4%) were withdrawn due to their smoking habit
(smoking pack years >10). Of these 45 subjects all were
willing to attend for a second visit that involved the same
protocol after withdrawal of their Montelukast for one
week, however, 3 did not attend visit 2 due to personal
reasons or illness. Of the 42 subjects who came for both
visits 1&2 (two weeks apart), all provided nasal samples at
visit 1 and 41 subjects provided nasal samples at visit 2.
Asthma control was quantified using the Juniper-ACQ
[22]. Spirometry was performed along with measurement of
exhaled NO. Exclusion criteria were aspirin-sensitivity,
previous nasal surgery or a history of bleeding diathesis,
recent epistaxis or an upper respiratory tract infection
within the past month. All participants provided written
Table 1 Subject characteristics.
Visit 1 (on
Montelukast)
N Z 42
Visit 2 (off
Montelukast)
N Z 42
Age (mean 95% CI) 42.6
(37.3e47.9)
42.6
(37.3e47.9)
Female n (%) 27 (64%) 27 (64%)
Asthma n (%) 42 (100%) 42 (100%)
Allergic rhinitis n (%) 17 (41%) 18 (43%)
Smoking history n (%)
Never 23 (54.8%) 23 (54.8%)
Ex 14 (33.3%) 14 (33.3%)
Current 1 (2.4%) 1 (2.4%)
Not applicable
(children)
4 (9.5%) 4 (9.5%)
Pack year smoking
mean (95% CI)
2.32
(0.86e3.8)
2.32
(0.86e3.8)
Medication n (%)
Short acting b2 agonist 32 (76%) 32 (76%)
Inhaled corticosteroid 38 (90%) 38 (90%)
Long acting b2 agonist 32 (76%) 32 (76%)
Leukotriene receptor
antagonist
42 (100%) 42 (100%)
Nasal corticosteroid 10 (24%) 10 (24%)
Anti-histamine 10 (24%) 10 (24%)
FEV1 (l) mean (95% CI) 2.71
(2.49e2.93)
2.65
(2.45e2.85)
FEV1 % predicted
mean (95% CI)
87.8%
(81.9e93.7)
86.2%
(80.6e91.8)
PEF (l/min) mean
(95% CI)
422
(387e457)
422
(387e457)
PEF % predicted
mean (95% CI)
95.1%
(88.3e102)
95.0%
(88.3e101)
FeNO mean (95% CI) 24.2
(19.3e29.1)
25.3
(18.6e32.0)
Rhinorrhoea
>1 h most days
12 (29%) 13 (31%)
Sneezing
>1 h most days
11 (26%) 5 (12%)
Nasal obstruction
>1 h most days
13 (31%) 17 (41%)
Nasal pruritis
>1 h most days
8 (19%) 9 (21%)
Juniper-ACQ score
mean (95% CI)
0.90
(0.69e1.11)
1.09
(0.88e1.31)
There were no statistically significant differences between
characteristics at visit 1 and 2.
Montelukast and nasal epithelial cells 1861informed consent and the study was approved by the North
of Scotland Research Ethics Service (10/S0802/37;
NCT01230437).
Collecting nasal AEC
All participants had nasal AEC sampling, those attending
after the withdrawal of Montelukast were also sampled at
the second visit. Nasal AEC were sampled by rotating a
2.7 mm diameter interdental brush (Dent-O-Care Ltd,
London, UK) against the inferior turbinate of each nostril
once. Immediately after removal from the nostril, the brush
was agitated in a 1.5 ml Eppendorf tube containing 1.0 ml
of specialised airway epithelial-specific serum-free media
(Bronchial Epithelial Growth Media, Lonza Ltd., Slough, UK)
and the resultant suspension subsequently seeded to a well
of a 6-well collagen coated plate (Greiner Bio-One, Frick-
enhausen, Germany) containing 2.0 ml of Bronchial
Epithelial Growth Media.
Cell culture and stimulation
Nasal AEC were cultured according to our established
methodology in Bronchial Epithelial Growth Media supple-
mented as previously described [15,16]. Briefly, primary
cultures of nasal AEC were sub-cultured by trypsinisation at
70e90% confluence and all experiments performed on
confluent cells at third passage in 12-well plates. The
epithelial nature of the cultured nasal cells was confirmed
by positive immunostaining with cytokeratin 13 and 19 and
negative staining with mAb specific for fibroblasts, endo-
thelial cells and macrophages (data not shown). Confluent
nasal AEC monolayers were dosed with
Montelukast concentrations of 1000 nM, 100 nM, 10 nM,
1 nM in Bronchial Epithelial Growth Medium and then were
stimulated with IL-1b and TNFa (both at 10 ng/ml) for
24 h or left unstimulated, as in our previous studies [15,16].
IL-1b and TNFa were selected as both are implicated in the
pathogenesis of many acute and chronic infectious and non-
infectious inflammatory diseases of the lung, often acting
synergistically. The following mediators implicated in
asthma causation were measured in nasal AEC culture su-
pernatants by cytometric bead array assay (BD Biosciences,
Oxford, UK): IL-6, IL-10, GM-CSF, RANTES, eotaxin and IFN-g
with sensitivity limits of 1.60 pg/ml, 0.13 pg/ml, 0.2 pg/ml,
0.002 pg/ml, 0.80 pg/ml, and 1.80 pg/ml respectively. IL-8
was measured by ELISA (Biolegend, Cambridge, UK) with a
sensitivity limit of 8.0 pg/ml. Samples with concentrations
lower than the sensitivity limits were designated as
0.00 pg/ml. After removal of the supernatant for storage at
20 C, nasal AEC were lysed and total protein content
measured with all results normalised to cellular protein
content. The effect of all concentrations of Montelukast
tested on unstimulated and cytokine-stimulated nasal AEC
viability was assessed using an acid phosphatase assay as
described [23].
Statistical analysis
Comparisons of the characteristics of those participating in
the first and second visits were made using McNemar’s testfor categorical variables and paired t-tests for the contin-
uous normally distributed parameters (e.g. lung function).
Non-parametric tests were used to analyse cytokine re-
sponses. The Mann Whitney U test was used to compare
unstimulated and stimulated cell cytokine output for sub-
jects with and without AR and the Wilcoxon signed ranks
test was used to investigate cytokine responses before
and after withdrawal of Montelukast. A non-parametric
repeated measures (Friedmann) test was used to investi-
gate the effects of increasing doses of Montelukast on
cytokine responses. Significance was assumed with
1862 A. Scaife et al.p < 0.05. Standard statistical software was used (SPSS
version 20). Based on our previous work stimulating nasal
AEC [15] with 20 subjects in each group (asthma with and
without AR) the study had 80% power to detect a 50% dif-
ference in IL-8 response at the 5% level of significance.Results
Study subjects
Table 1 depicts the demographic details for the 42 in-
dividuals who took part in the study. Successful cultures of
nasal AEC were established from 17 (40%) of subjects on
their first study visit and from 14 (34%) of subjects on their
second visit one week after withdrawal of Montelukast. In
10 subjects nasal AEC were successfully cultured from both
the first and second visit nasal AEC samples. Loss of cultures
was due to either failure of cells to grow (40%) or because
of infection (14%). Nasal corticosteroid treatment was
associated with a higher likelihood of culture success (i.e.
AEC cultured on 1 assessment): nasal corticosteroid
treatment was prescribed for 8 (38%) of the 21 individuals
where culture was successful and 2 (10%) of the 21 subjects
with no successful cultures, (p < 0.03, data not shown).
Groups where AEC culture was and was not successful were
otherwise similar.
Mediator release with and without allergic rhinitis
We observed no differences between patients with and
without AR in release of any mediators with or without IL-1/
TNF stimulation and before or after Montelukast with-
drawal (Fig. 1).
In vitro addition of Montelukast to cultures
In vitro Montelukast significantly suppressed the release of
IL-8 (pZ 0.016), IL-6 (pZ 0.003), RANTES (pZ 0.002) and
IFN-g (p Z 0.046) in a dose dependent manner in unsti-
mulated cultures (Fig. 2). The association between Mon-
telukast dose and IL-8, IL-6, RANTES and IFN-g responsesa
Figure 1 a: Box and whisker plot; IL-8, IL-6, IL-10, eotaxin, GM-C
from subjects with asthma with and without allergic rhinitis, visit 1
p > 0.05 (Mann Whitney U test). *a consequence of undetectable c
CSF, RANTES, interferon-g secretion by nasal AEC stimulated by TN
rhinitis, visit 1. All differences between asthma and asthma þ al
undetectable cytokine.was evident if responses were expressed as absolute values,
as differences from control cultures without Montelukast or
as ratios to control cultures without Montelukast. There
was no difference in mediator release after Montelukast
exposure to nasal AEC after stimulation with IL-1 and TNF.
Montelukast treatment at any concentration was not asso-
ciated with reduced viability of unstimulated or cytokine-
stimulated nasal AEC (data not shown).
Mediator release after clinical withdrawal of Montelukast
There were 10 paired nasal AEC cultures from 5 asthmatic
subjects with and 5 subjects without AR. Withdrawal of
Montelukast from these patients for one week was not
associated with changes in symptoms of AR or asthma
(Table 1). Montelukast withdrawal in vivo was associated
with increases in IL-8, GM-CSF and RANTES secretion from
nasal AEC cultured from subjects with asthma and allergic
rhinitis but not from subjects with asthma alone. For sub-
jects with asthma þ AR in vivo Montelukast withdrawal was
associated with increased IL-8 release (in both unstimu-
lated and stimulated culture) (Fig. 3a), GM-CSF secretion
was increased after withdrawal of Montelukast (only in
stimulated culture, Fig. 3b), and RANTES secretion was
increased (only in unstimulated culture Fig. 3c). Mon-
telukast withdrawal was not associated with significant
changes in other mediators (data not shown).Discussion
In the present study we compared inflammatory cytokine
and chemokine production by nasal AEC cultured from
asthmatic patients with and without concomitant allergic
rhinitis (AR) and also examined whether Montelukast has
anti-inflammatory effects on nasal AEC secretion both
in vitro and in vivo. We observed that Montelukast sup-
pressed the release of IL-8, IL-6, RANTES and interferon-g,
in a dose dependent manner in unstimulated cultures
in vitro. Withdrawal of Montelukast therapy for one week
was associated with increased in vitro nasal AEC secretionb
SF, RANTES, interferon-g secretion by unstimulated nasal AEC
. All differences between asthma and asthma þ allergic rhinitis
ytokine. b: Box and whisker plot; IL-8, IL-6, IL-10, eotaxin, GM-
F-a/IL-1 from subjects with asthma with and without allergic
lergic rhinitis p > 0.05 (Mann Whitney U ). *a consequence of
Figure 2 a: Effect of in vitro Montelukast on IL-8 secretion by unstimulated nasal AEC from subjects (nZ 17) visit 1. pZ 0.016
(Friedman test). IL-8 expressed as median (25th, 75th centile) ratio to control levels of IL-8 secretion (in the absence of Mon-
telukast) by unstimulated nasal AEC. b: Effect of in vitro Montelukast on IL-6 secretion by unstimulated nasal AEC from subjects
(nZ 17) visit 1. pZ 0.003 (Friedman test). IL-6 expressed as median (25th, 75th centile) ratio to control levels of IL-6 secretion
(in the absence of Montelukast) by unstimulated nasal AEC. c: Effect of in vitro Montelukast on RANTES secretion by unstimulated
nasal AEC from subjects (n Z 17) visit 1. p Z 0.002 (Friedman test). RANTES expressed as median (25th, 75th centile) ratio to
control levels of RANTES secretion (in the absence of Montelukast) by unstimulated nasal AEC. d: Effect of in vitro Montelukast on
IFN-g secretion by unstimulated nasal AEC from subjects (n Z 17) visit 1. p Z 0.046 (Friedman test). IFN-g expressed as median
(25th, 75th centile) ratio to control levels of IFN-g secretion (in the absence of Montelukast) by unstimulated nasal AEC.
Montelukast and nasal epithelial cells 1863of IL-8 and RANTES but only in subjects with AR. These
findings suggest that, independent of nasal corticosteroid
use, Montelukast has an anti-inflammatory effect on nasal
AEC mediator secretion in subjects with asthma and allergic
rhinitis.
There are a small number of studies that have examined
the effect of Montelukast on the secretory function of
lower airway cells [24] [25], although both were performed
using cell lines rather than primary cells. Consistent with
our findings, Mullol and colleagues [26] demonstrated
inhibitory effects by Montelukast on foetal bovine serum-
stimulated nasal mucosal or polyp AEC production of GM-
CSF, IL-6 and IL-8. However, these authors also reported
no significant effects by Montelukast on constitutive
release of these cytokines by their nasal AEC. The reasons
for these discrepancies are not clear but Mullol et al.
investigated the in vitro effect of a single concentration of
Montelukast which may not have been sufficient to suppress
nasal AEC mediator release whereas we used a concentra-
tion range of Montelukast.
One of our aims was to determine whether AR was
associated with increased nasal AEC release and, although
there was no difference in cytokine and chemokine releasebetween the asthmatic subjects with and without AR, it is
likely that treatment with Montelukast was suppressing IL-8
and RANTES release among those with AR, meaning that AR
is associated with increased nasal AEC mediator release.
We suggest that nasal AEC release of IL-8 and RANTES in
unstimulated culture is not a valid reflection of bronchial
AEC mediator release for patients with AR because there is
the possibility that the increased mediator release may not
be reflected in the bronchial mucosa.
There are a number of factors which should be
considered when interpreting our results. Although the
study recruited the intended number of subjects from
primary and secondary care, the associations with nasal
AEC are based on rather low numbers of subjects, partic-
ularly in relation to the Montelukast withdrawal compo-
nent of the study for which data were available from a
total of 10 successful paired cultures. The successful
culturing of nasal AEC from w40% of subjects in this study
through failure of primary culture and infection is lower
than the success rate that we have achieved in previous
studies of nasal brushings taken from adults [15] or chil-
dren [16]. Our low culture rate may reflect a constitutive
resistance to culture by nasal AEC from subjects with
a b
c
Figure 3 a: Box and whisker plot demonstrating the effect of withdrawing Montelukast for one week on IL-8 secretion by
stimulated and unstimulated nasal AEC from subjects with (nZ 5) and without allergic rhinitis (nZ 5). p values refer to difference
in responses on and off Montelukast, computed using Wilcoxon signed ranks test. b: Box and whisker plot demonstrating the effect
of withdrawing Montelukast for one week on GM-CSF secretion by stimulated and unstimulated nasal AEC from subjects with
(n Z 5) and without allergic rhinitis (n Z 5). p values refer to difference in responses on and off Montelukast, computed using
Wilcoxon signed ranks test. c: Box and whisker plot demonstrating the effect of withdrawing Montelukast for one week on RANTES
secretion by stimulated and unstimulated nasal AEC from subjects with and without allergic rhinitis. p values refer to difference in
responses on and off Montelukast, computed using Wilcoxon signed ranks test.
1864 A. Scaife et al.asthma. Parker et al. [27] demonstrated that cells
removed at bronchial brushing and cultured under air-
liquid interface conditions differentiate into different
proportions of columnar epithelial cells and goblet cells in
asthmatic and non-asthmatic children and we do not know
whether our cultured cells (confirmed as epithelial cells)
were one or both of these cell types. Although our previous
work has reported that paired cultures of nasal and
bronchial epithelial cells from adults [15] or children [16]
are similar in size, shape and growth characteristics with
a number of similarities in cytokine/chemokine secretion,
we cannot comment on the possible effects of Montelukast
on bronchial AEC. Clearly the current study would need to
be repeated with bronchial AEC cultures to address this
issue. The mediators of interest in the present study were
those measured in our previous studies [15,16]. We
acknowledge there are many other mediators implicated
in asthma and AR, but measurement of additionalmediators was beyond the scope of the present study
where the focus was on Montelukast function.
Montelukast has a number of well-documented anti-in-
flammatory effects both in vivo and in vitro and some of
these appear independent of cysLT1R antagonism [6]. The
findings in this study contribute to this growing body of
knowledge but do not address the actual mechanism by
which Montelukast exerts these particular effects. Further
elucidation of these mechanisms could lead to the devel-
opment of novel therapeutic agents that target AEC ab-
normalities that contribute to asthma and allergic airways
disease. This study was limited to subjects with asthma
with a documented clinical response to Montelukast, it
would be instructive to investigate whether the in vitro
dose dependent suppression of IL-8, IL-6, RANTES and
interferon-g secretion by nasal AEC is demonstrable in
subjects with asthma who do not have a clinical response to
Montelukast. Further research along this line of
Montelukast and nasal epithelial cells 1865investigation could result in the development of a relatively
simple test to predict which patients with asthma are likely
to gain beneficial effect from Montelukast.
In summary, in subjects with a documented clinical
response to Montelukast, we have observed a number of
inhibitory effects by Montelukast on nasal AEC function
suggesting a direct effect of Montelukast on nasal AEC. To
date this is the first study to have demonstrated such ef-
fects on nasal AEC in vitro with clinical in vivo correlates.
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